One common need among domestic Chinese pharmaceutical companies is understanding the value of their assets or projects in America. The treatment algorithms, access landscape, and pricing are very different between China and the United States.

By leveraging our access to US key opinion leaders, as well as secondary data assets (e.g. claims data and EHR data), we are able to help our Chinese clients understand both the clinical and financial nuances of out-licensing or even building a team in the United States.

We have experience working with three unique sets of clients in our forecasting and valuation services:

• Start-up clinical stage Chinese companies looking to raise capital or find a strategic partner
• MNC pharmaceutical companies looking to acquire or partner with clinical stage companies
• Private equity and venture capital funds looking to invest in clinical stage Chinese companies

We leverage primary market research, secondary data assets, and key industry expert opinions to estimate revenue and profit under various market scenarios to value clinical assets, identify key value drivers, and guide investment or strategic partnership decisions

Many of our clients are currently engaged in clinical development and / or commercial partnerships and require ongoing alliance management support to facilitate communication and collaboration between the two companies.

We have represented MNC pharmaceutical companies, emerging biotechs, and academic institutions that have engaged domestic Chinese partners for commercialization rights in greater China. By combining our understanding of both the US and Chinese markets, as well as the language and cultural dynamics of both countries, we are able proactively identify and capture maximum value in future collaboration opportunities, rather than simply reactively manage existing contracts.